RT Journal Article
SR Electronic
T1 Multiplexed Detection of Sepsis Markers in Whole Blood using Nanocomposite Coated Electrochemical Sensors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.03.20224683
DO 10.1101/2020.11.03.20224683
A1 Zupančič, Uroš
A1 Jolly, Pawan
A1 Estrela, Pedro
A1 Moschou, Despina
A1 Ingber, Donald E.
YR 2020
UL http://medrxiv.org/content/early/2020/11/04/2020.11.03.20224683.abstract
AB Sepsis is a leading cause of mortality worldwide that is difficult to diagnose and manage because this requires simultaneous analysis of multiple biomarkers. Electrochemical detection methods could potentially provide a way to accurately quantify multiple sepsis biomarkers in a multiplexed manner as they have very low limits of detection and require minimal sensor instrumentation; however, affinity-based electrochemical sensors are usually hampered by biological fouling. Here we describe development of an electrochemical detection platform that enables detection of multiple sepsis biomarkers simultaneously by incorporating a recently developed nanocomposite coating composed of crosslinked bovine serum albumin containing a network of reduced graphene oxide nanoparticles that prevents biofouling. Using nanocomposite coated planar gold electrodes, we constructed a procalcitonin sensor and demonstrated sensitive PCT detection in undiluted serum and clinical samples, as well as excellent correlation with a conventional ELISA (adjusted r2 = 0.95). Sensors for two additional sepsis biomarkers — C-reactive protein and pathogen-associated molecular patterns — were developed on the same multiplexed platform and tested in whole blood. Due to the excellent antifouling properties of the nanocomposite coating, all three sensors exhibited specific responses within the clinically significant range without any cross-reactivity in the same channel with low sample volume. This platform enables sensitive simultaneous electrochemical detection of multiple analytes in human whole blood, which can be expanded further to any target analyte with an appropriate antibody pair or capturing probe, and thus, may offer a potentially valuable tool for development of clinical point-of-care diagnostics.Competing Interest StatementGrant funding for research but no other competing interestFunding StatementThis work was supported by Defense Advanced Research Projects Agency (DARPA) Contract W911NF-16-C-0050, the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Rosetrees Trust (project M681); the salary of U. Zupančič was provided by University of Bath and Santander. The project was supported by the U.S. Army Research Office, and the content of the information does not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patient blood samples were collected at the Beth Israel Deaconess Medical Center (BIDMC) Emergency Department as part of a previous clinical study. The study was approved by the BIDMC Committee on Clinical Investigations, and patients or legal designees signed written informed consent. The collection of control samples was approved by the Harvard University Faculty of Medicine Committee on Human Studies (protocol number M20403-101) in accordance with all national or local guidelines and regulations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on requestAPPC4-aminophenyl-phosphorylcholineAFMatomic force microscopyAuNWgold nanowiresBSABovine serum albuminCRPC-reactive proteinCVcyclic voltammetryECelectrochemicalEDC1-Ethyl-3-(3-dimethylaminopropyl)carbodiimideELISAenzyme-linked immunosorbent assayFDAFood and Drug AdministrationFE-SEMfield-emission electron scanning microscopeGAglutaraldehydeIL-6interleukine-6LODlimit of detectionMBLmannose binding lectinNHSN-HydroxysuccinimidePAMPspathogen associated molecular patternsPBSphosphate buffer salinePBSTphosphate buffer saline with 0.5% tween 20PCphosphocholinePCTprocalcitoninPDMSpolydimethylsiloxanePOCpoint-of-carerGOxreduced graphene oxiderGOx-NH2reduced graphene oxide with amine functionalizationRMSroom mean squareRTroom temperatureSPRsurface plasmon resonanceTBSTris-buffered salineTBSTTris-buffered saline with 0.5% tween 20TMB3,3’,5,5’-TetramethylbenzidineWEworking electrode.